EpilepsyGTx and Viralgen partner to scale AAV gene therapy production for refractory epilepsy
Executive summary: EpilepsyGTx has partnered with specialized CDMO Viralgen to support the scalable production of its EPY201 gene therapy program using AAV vectors. Successful scaling of AAV production is a prerequisite for transitioning from preclinical development to human clinical trials for focal refractory epilepsy.
Who is involved: EpilepsyGTx, Viralgen
Likely next: Initiation of first-in-human clinical trials and submission of regulatory filings for EPY201.
The strategic collaboration between EpilepsyGTx and Viralgen marks a critical step in de-risking the EPY201 program as it approaches human clinical trials. By integrating Viralgen’s expertise in adeno-associated virus (AAV) vector production, EpilepsyGTx is proactively addressing one of the most significant hurdles in the biotechnology sector: the transition from preclinical validation to scalable, high-quality manufacturing. In the specialized field of gene therapy for refractory epilepsy, the ability to produce consistent, clinical-grade vectors is often as vital to regulatory success as the therapeutic efficacy itself. This partnership signals a broader industry trend where specialized biotech firms are securing manufacturing partnerships early to avoid the capacity bottlenecks that frequently stall late-stage development. For investors and market observers, this move suggests a disciplined approach to operational readiness. As the EPY201 program moves toward its first clinical milestones, the success of this collaboration will be measured by the efficiency of the scale-up process. If Viralgen can successfully deliver the necessary manufacturing throughput, it could establish a repeatable blueprint for managing the complex supply chain requirements inherent in AAV-based neurological interventions.
What's next — scenarios
Base: successful scale-up for clinical trials (60%)
Smooth transition to Phase I human trials for EPY201.
- Successful completion of AAV vector potency assays
- FDA/EMA approval for IND application
Downside: manufacturing scalability issues (25%)
Delays in human trials due to vector purity or quantity shortages.
- Failure to meet GMP standards during scale-up
- High variability in AAV vector concentration
Upside: rapid clinical progression (15%)
Accelerated development timeline following positive manufacturing data.
- Successful NGS quality control results
- Seamless transfer of technology from lab to large-scale CDMO
What to watch
- Announcement of First-in-Human clinical trial commencement
- Results of regulatory inspections at Viralgen facilities
- Data from NGS sequence analysis for vector purity
Timeline
- — EpilepsyGTx y Viralgen impulsan un programa de terapia génica con vectores AAV para la epilepsia (PR Newswire)
- — TSC Alliance and Apertura Gene Therapy Complete Preclinical Pilot Study Evaluating AAV Gene Therapy Approach Designed for TSC1 (PR Newswire)
- — OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme (GlobeNewswire)
Analysis — what this means
Likely next events
- First-in-human clinical trial start date (TBD)
- Regulatory filing for EPY201
Sectors affected
- Gene therapy developers
- AAV CDMOs
- Neurology pharmaceutical companies
Regulatory implications
- GMP compliance requirements for AAV production
- IND/CTA submission protocols for gene therapies
Historical parallels
- Oxford BioTherapeutics (OXB) partnership with Plowshare Therapies (2026) for AAV manufacturing
Key entities
Sources
- EpilepsyGTx y Viralgen impulsan un programa de terapia génica con vectores AAV para la epilepsia — PR Newswire
- OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme — GlobeNewswire
- TSC Alliance and Apertura Gene Therapy Complete Preclinical Pilot Study Evaluating AAV Gene Therapy Approach Designed for TSC1 — PR Newswire